...
首页> 外文期刊>BMC Neurology >Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study
【24h】

Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study

机译:难治性偏头痛或偏头痛且对托吡酯不耐受的患者经皮眶上神经刺激的临床经验:一项前瞻性探索性临床研究

获取原文

摘要

Background Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly? device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly? in a cohort of migraine patients previously refractory or intolerant to topiramate prophylaxis. Methods A prospective, multi-center clinical study was performed in patients diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment requiring prevention with Cefaly? according to the treating physician’s suggestion. A 1-month period of baseline observation was followed by a 3-month period of observation during the use of transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly? as the only preventive treatment. Results A small but statistically significant decline was shown over time in the number of days with headache (HA), the number of days with HA with intensity ≥5/10, and the number of days with use of acute medication after 3?months ( p Conclusion Three-months of preventive treatment for episodic or chronic migraine with t-SNS proved to be an effective, safe and well tolerated option for the treatment of patients with migraine who were intolerant or did not respond to topiramate. Trial registration ClinicalTrials NCT03125525 . Registered 21 April 2017.
机译:背景偏头痛是西方人群中十大致残疾病之一。非侵入性神经刺激,包括Cefaly?装置,用于治疗各种类型的疼痛是相对较新的关注领域。本研究的目的是探讨Cefaly?的临床经验。在先前偏头痛患者难治或不耐受的偏头痛患者队列中。方法对先前诊断为发作性或慢性偏头痛但先前未能接受托吡酯治疗且需要用Cefaly?预防的发作性或慢性偏头痛患者进行了一项前瞻性,多中心临床研究。根据主治医师的建议在使用Cefaly?经皮眶上神经刺激(t-SNS)的过程中,基线观察为1个月,随后为3个月。作为唯一的预防方法。结果显示,随着时间的推移,头痛(HA)的天数,强度≥5/ 10的HA的天数以及3个月后使用急性药物的天数随时间推移呈小幅下降,但具有统计学意义(结论结论对于不耐受或对托吡酯无反应的偏头痛患者,三个月的t-SNS预防性发作性或慢性偏头痛治疗是一种有效,安全且耐受性良好的选择,临床注册临床试验NCT03125525。 2017年4月21日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号